AffinityAI

AffinityAI is a Danish biotech startup that delivers custom protein binders using advanced AI-driven design methods. Founded by researchers with deep experience in antibody development, the company addresses the traditional bottlenecks in binder discovery—such as high cost, slow timelines, and unpredictable yields—by offering streamlined AI-generated alternatives.

Its core offering, branded as Designerbodies™, comprises precision-engineered protein binders optimized for strong affinity, thermal stability, and expression in microbial systems. These engineered molecules come with high-resolution structural mapping of binding interfaces, enabling confidence in targeting and performance.

AffinityAI’s proprietary platforms, ARCANE™ and RAVEN™, underpin the AI design and expression workflow, significantly accelerating research timelines—clients can receive custom binder solutions up to five times faster than with conventional antibody production. The company emphasizes sustainable, animal-free production methods and supports scalable biomanufacturing.

Its clients include teams in pharmaceutical development, diagnostic assay design, academic labs, and clinical research settings. Whether used for target validation, biomarker detection, or companion diagnostics, AffinityAI positions its Designerbodies as precision tools that reduce risk while boosting reproducibility.

Built on rigorous academic research, the company's foundation reflects peer-reviewed innovations in generative protein modeling, binder discovery, and high-throughput validation, positioning it at the intersection of AI innovation and practical life-science applications.

Keywords: AI-designed protein binders, Designerbodies™, generative biology, ARCANE™, RAVEN™, rapid binder discovery, structural epitope mapping, high affinity reagents, animal-free production, biotech innovation, diagnostics, pharmaceutical R&D, Denmark startup